Under construction – not a live service

Skip to content

Frontlight Research

Institution

Princess Margaret Cancer Centre

Toronto, CanadaWebsite

Also known as: Princess Margaret Hospital

361running trials
147closed trials
35,658publications (OpenAlex)

Running trials

Not yet recruiting
Positioning in RT - Supine vs. Upright
NCT07765069· University Health Network, Toronto· Source
Not yet recruiting
Personalized Adaptive Radiotherapy for Hepatocellular Carcinoma
NCT07895732· Phase 3· University Health Network, Toronto· Source
Not yet recruiting
Optimizing Response to Immunotherapy With Online Adaptive Pulsed Radiotherapy in Incurable Head and Neck Cancers
NCT07888816· Phase 2· University Health Network, Toronto· Source
Recruiting
A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025).
NCT07722611· Phase 2/3· Merck Sharp & Dohme LLC· Source
Recruiting
Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC
NCT07698106· Phase 1/2· University Health Network, Toronto· Source
Not yet recruiting
Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer
NCT06836726· Phase 2· University Health Network, Toronto· Source
Recruiting
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
NCT07623161· Phase 3· Takeda· Source
Recruiting
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
NCT07804186· Phase 3· IDEAYA Biosciences· Source
Recruiting
A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
NCT07586202· Phase 2· Janssen Research & Development, LLC· Source
Not yet recruiting
Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer
NCT07665684· Phase 1/2· University Health Network, Toronto· Source
Recruiting
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
NCT07644559· Phase 2· Verastem, Inc.· Source
Recruiting
Simulation-Free Celiac Plexus Pain Ablation Using Stereotactic Body Radiotherapy in Patients With Cancer-Related Celiac Pain
NCT07636382· University Health Network, Toronto· Source
Recruiting
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
NCT07413939· Phase 2/3· Hoffmann-La Roche· Source
Recruiting
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
NCT07570173· Phase 2/3· Merck Sharp & Dohme LLC· Source
Recruiting
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
NCT07441694· Phase 1· Incyte Corporation· Source
Recruiting
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
NCT07519772· Phase 1/2· Merck Sharp & Dohme LLC· Source
Recruiting
A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)
NCT07408063· Phase 2· University Health Network, Toronto· Source
Recruiting
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
NCT07419295· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
Hypersight and Ethos In Pediatric Radiotherapy
NCT07528547· University Health Network, Toronto· Source
Recruiting
Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)
NCT07524114· University Health Network, Toronto· Source
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
NCT07221149· Phase 2/3· Bristol-Myers Squibb· Source
Recruiting
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07287150· Phase 2· Hoffmann-La Roche· Source
Recruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445· Phase 3· Revolution Medicines, Inc.· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
NCT07284849· Phase 3· Incyte Corporation· Source
Recruiting
A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
NCT07227025· Phase 1/2· Janssen Research & Development, LLC· Source
Not yet recruiting
Trauma-Focused Managing Cancer And Living Meaningfully (CALM-TF) for Newly Diagnosed and Recurrent Ovarian Cancer
NCT07286162· Phase 3· University Health Network, Toronto· Source
Recruiting
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
NCT07360314· Phase 1· EMD Serono Research & Development Institute, Inc.· Source
Recruiting
A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer
NCT07258407· Phase 1/2· T.O.A.D. Oncology SA· Source
Recruiting
Neoadjuvant Darovasertib in Primary Uveal Melanoma
NCT07015190· Phase 3· IDEAYA Biosciences· Source
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
NCT07216703· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
NCT07195695· Phase 3· Boehringer Ingelheim· Source
Recruiting
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
NCT07188558· Phase 3· Lyell Immunopharma, Inc.· Source
Recruiting
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
NCT07128199· Phase 3· Taiho Oncology, Inc.· Source
Recruiting
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07225946· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
NCT07222800· Phase 3· Pfizer· Source
Active, not recruiting
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
NCT07288203· Phase 2· Iovance Biotherapeutics, Inc.· Source
Recruiting
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
NCT07223047· Phase 1/2· Bristol-Myers Squibb· Source
Recruiting
A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
NCT07241039· Phase 1· AbbVie· Source
Active, not recruiting
Actinium Therapy for Late-stage Aggressive Sarcomas
NCT07156565· Phase 1· Ratio Therapeutics, Inc.· Source
Recruiting
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
NCT07100080· Phase 2/3· Bristol-Myers Squibb· Source
Active, not recruiting
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
NCT07076121· Phase 2/3· Bristol-Myers Squibb· Source
Recruiting
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804· Phase 3· Eli Lilly and Company· Source
Recruiting
Phase II Study of Daily Adaptive Radiotherapy for Submandibular Gland-sparing in Head and Neck Cancer
NCT07348887· University Health Network, Toronto· Source
Recruiting
M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
NCT07166601· Phase 1· EMD Serono Research & Development Institute, Inc.· Source
Recruiting
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06988488· Phase 1/2· Celgene· Source
Recruiting
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
NCT07106762· Phase 2/3· Bristol-Myers Squibb· Source
Recruiting
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280· Phase 3· Pfizer· Source
Recruiting
PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
NCT07190469· Phase 1· ProteinQure Inc.· Source

Showing 50 of 361.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Lung cancer35 recruiting
Prostate cancer23 recruiting
Colorectal cancer22 recruiting
Pancreatic cancer22 recruiting
Head and neck cancer19 recruiting
Childhood cancers18 recruiting
Ovarian cancer18 recruiting
Melanoma14 recruiting
Gastric and oesophageal cancer9 recruiting
Multiple myeloma9 recruiting
Chronic lymphocytic leukaemia6 recruiting
Diffuse large B-cell lymphoma6 recruiting
Endometrial cancer6 recruiting
Metastatic breast cancer6 recruiting
Myeloproliferative neoplasms6 recruiting
Sarcoma6 recruiting
Triple-negative breast cancer6 recruiting
Bladder cancer5 recruiting
Cervical cancer5 recruiting
Myelodysplastic syndromes5 recruiting
Acute myeloid leukaemia4 recruiting
Chronic myeloid leukaemia4 recruiting
Liver and biliary tract cancer4 recruiting
Mantle cell lymphoma4 recruiting
Acute lymphoblastic leukaemia3 recruiting
Follicular lymphoma3 recruiting
Glioblastoma3 recruiting
Kidney cancer3 recruiting
Neuroendocrine tumours2 recruiting
Coeliac disease1 recruiting
Hodgkin lymphoma1 recruiting
Meningioma1 recruiting
Thyroid cancer1 recruiting

Closed trials

Completed
A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)
NCT06894771· Phase 1· Merck Sharp & Dohme LLC· Source
Completed
A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
NCT06618001· Phase 1· Janssen Research & Development, LLC· Source
Completed
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
NCT06637423· Phase 1/2· Merck Sharp & Dohme LLC· Source
Completed
A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)
NCT06460961· Phase 1· Merck Sharp & Dohme LLC· Source
Completed
A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NCT06131398· Phase 1· Amgen· Source
Recruiting
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478· Phase 2· Daiichi Sankyo· Source
Completed
Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma
NCT06058793· Phase 3· Boehringer Ingelheim· Source
Terminated
Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
NCT05712694· Phase 3· Polaris Group· Source
Completed
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
NCT06036836· Phase 2· Merck Sharp & Dohme LLC· Source
Terminated
Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors
NCT05909995· Phase 1· Incyte Corporation· Source
Withdrawn
mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT05918250· Phase 1· ModernaTX, Inc.· Source
Completed
A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
NCT05975073· Phase 1/2· Amgen· Source
Terminated
A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors
NCT05576077· Phase 1· Turnstone Biologics, Corp.· Source
Completed
A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001)
NCT05594043· Phase 1· Merck Sharp & Dohme LLC· Source
Completed
Rehabilitation for People With Advanced Cancer
NCT05424068· University Health Network, Toronto· Source
Completed
Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15
NCT05546476· Phase 2· Pfizer· Source
Terminated
Neoadjuvant Combination of Atezolizumab/Bevacizumab Versus Neoadjuvant Radiation Therapy
NCT05137899· Phase 2· Ontario Clinical Oncology Group (OCOG)· Source
Completed
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)
NCT05508867· Phase 2· Merck Sharp & Dohme LLC· Source
Terminated
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
NCT05325866· Phase 1/2· Amgen· Source
Completed
A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review
NCT05444972· AbbVie· Source
Completed
A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma
NCT05419388· Phase 2· Hoffmann-La Roche· Source
Terminated
A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)
NCT05269355· Phase 2/3· PTC Therapeutics· Source
Completed
A Web-based Peer Navigation Program for Men With Prostate Cancer
NCT05041504· University Health Network, Toronto· Source
Completed
......SMARTEST Trial......
NCT05380713· Phase 2· University Health Network, Toronto· Source
Terminated
Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors
NCT07121829· Phase 1· Day One Biopharmaceuticals, Inc.· Source
Completed
A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With Glioblastoma
NCT05187624· Phase 1· Hoffmann-La Roche· Source
Completed
Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma
NCT05218499· Phase 2/3· Boehringer Ingelheim· Source
Terminated
Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
NCT05305040· Phase 2/3· AlloVir· Source
Completed
Timing of Post-prostatectomy PSMA Imaging
NCT05008900· Phase 2· University Health Network, Toronto· Source
Completed
Predicting Radiological Extranodal Extension in Oropharyngeal Carcinoma Patients Using AI
NCT05565313· Maastricht Radiation Oncology· Source
Terminated
Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML
NCT05275439· Phase 1· Shattuck Labs, Inc.· Source
Terminated
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
NCT05241873· Phase 1· Blueprint Medicines Corporation· Source
Withdrawn
Mapping 3D Bladder
NCT05260788· University Health Network, Toronto· Source
Terminated
Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer
NCT04966676· Phase 2· University Health Network, Toronto· Source
Recruiting
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
NCT05139017· Phase 2/3· Merck Sharp & Dohme LLC· Source
Completed
A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)
NCT05144841· Phase 2· Merck Sharp & Dohme LLC· Source
Completed
Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patient
NCT05368207· University Health Network, Toronto· Source
Completed
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)
NCT05064059· Phase 3· Merck Sharp & Dohme LLC· Source
Terminated
Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
NCT04892446· Phase 2· Gilead Sciences· Source
Terminated
MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
NCT05090566· Phase 2· Pfizer· Source
Completed
S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers
NCT05162755· Phase 1· Institut de Recherches Internationales Servier· Source
Terminated
Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC
NCT05166577· Phase 1· Viracta Therapeutics, Inc.· Source
Completed
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
NCT05007106· Phase 2· Merck Sharp & Dohme LLC· Source
Terminated
ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2)
NCT04752358· Phase 2· Adaptimmune· Source
Terminated
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).
NCT04949256· Phase 3· Merck Sharp & Dohme LLC· Source
Terminated
Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
NCT04778397· Phase 3· Gilead Sciences· Source
Terminated
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
NCT04862780· Phase 1· Blueprint Medicines Corporation· Source
Completed
To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)
NCT04894591· Jazz Pharmaceuticals· Source
Completed
An Observational Study to Evaluate the Clinical Utility of the Oncomine Precision Assay Within the Exactis Network
NCT04564079· Exactis Innovation· Source
Completed
A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface
NCT04752215· Phase 1· Boehringer Ingelheim· Source

Showing 50 of 147.

Registry name variants (82)

Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.

Princess Margaret Cancer Centre
Toronto, Ontario M5G 2C1
297 trials
Princess Margaret Cancer Center
Toronto, Ontario M5G 1Z5
56 trials
Princess Margaret Hospital
Toronto, M5G 1Z5
54 trials
Princess Margaret Cancer Centre (Site 0101)
Toronto, Ontario M5G 2M9
4 trials
Princess Margaret Cancer Centre (Site 0202)
Toronto, Ontario M5G 2M9
4 trials
Princess Margaret Cancer Centre (Site 0102)
Toronto, Ontario M5G 2M9
3 trials
- NCT06863272A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
  Contact: Study Coordinator
- NCT06077760A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
- NCT04221945Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)
Princess Margaret Cancer Centre (Site 0107)
Toronto, Ontario M5G 2M9
3 trials
- NCT03924895Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
- NCT03924856Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
- NCT03834519Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)
Princess Margaret Hospital (Ontario)
Toronto, Ontario M4X 1K9
3 trials
- NCT04956640Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
- NCT04666038Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- NCT02246621A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
The Princess Margaret Cancer Centre
Toronto, Ontario M5G 2C4
3 trials
- NCT06561048Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
  Contact: Anca Prica (principal investigator)
- NCT07377747Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma
  Contact: Charles Catton
- NCT06343402Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
  Contact: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
UHN - Princess Margaret Hospital
Toronto, Ontario M5G 2M9
3 trials
- NCT04176081Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer
  Contact: Sunakshi Chowdhary
- NCT01650701A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma
- NCT01924819Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma
Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology (Site 0200)
Toronto, Ontario M5G 2M9
2 trials
- NCT05458297A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
- NCT05139017A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
  Contact: Toll Free Number
Princess Margaret Cancer Centre - Oncology Department
Toronto, Ontario M5G 2C4
2 trials
- NCT05794906A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
- NCT05537740A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors
Princess Margaret Cancer Centre (Site 0001)
Toronto, Ontario M5G 2M9
2 trials
- NCT06997497A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
  Contact: Study Coordinator
- NCT06686394Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
  Contact: Study Coordinator
Princess Margaret Cancer Centre (Site 0003)
Toronto, Ontario M5G 2M9
2 trials
- NCT06637423A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
- NCT06305767A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
Princess Margaret Cancer Centre (Site 0051)
Toronto, Ontario M5G 2M9
2 trials
- NCT03783078Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)
- NCT03040999Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)
Princess Margaret Cancer Centre (Site 0203)
Toronto, Ontario M5G 2M9
2 trials
- NCT06305754Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
- NCT03675737Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)
Princess Margaret Cancer Centre (Site 0310)
Toronto, Ontario M5G 2M9
2 trials
- NCT06312176A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
  Contact: Study Coordinator
- NCT05508867A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)
#2001, Princess Margaret Cancer Centre
Toronto, Ontario M5G 2C1
1 trial
- NCT04855656Study of Lunresertib Alone or in Combination With RP-3500 or Zedoresertib (Debio 0123) in Patients With Advanced Solid Tumors
  Contact: Debiopharm International S.A
Princess Margaret Cancer Center (Site 0101)
Toronto, Ontario M5G 2M9
1 trial
- NCT06894771A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)
Princess Margaret Cancer Center (Site 0102)
Toronto, Ontario M5G 2M9
1 trial
- NCT07570173A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
  Contact: Study Coordinator
Princess Margaret Cancer Center (Site 0116)
Toronto, Ontario M5G 2M9
1 trial
- NCT07060807A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
  Contact: Study Coordinator
Princess Margaret Cancer Center (Site 0609)
Toronto, Ontario M5G 2M9
1 trial
- NCT06952504A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
  Contact: Study Coordinator
Princess Margaret Cancer Centre (Adults only)
Toronto, Ontario M5G 2M9
1 trial
- NCT03394365A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
  Contact: Igor Novitzky Basso, MD
Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology (Site 0100)
Toronto, Ontario M5G 2M9
1 trial
- NCT05144841A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)
Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology (Site 0155)
Toronto, Ontario M5G 2M9
1 trial
- NCT05064059A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)
Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology (Site 0406)
Toronto, Ontario M5G 2M9
1 trial
- NCT04728893Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
  Contact: Study Coordinator
Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology (Site 1102)
Toronto, Ontario M5G 2M9
1 trial
- NCT05933577A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
Princess Margaret Cancer Centre /ID# 153651
Toronto, Ontario M5G 2M9
1 trial
- NCT02993523A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
Princess Margaret Cancer Centre /ID# 249748
Toronto, Ontario M5G 2M9
1 trial
- NCT05444972A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review
Princess Margaret Cancer Centre /ID# 268277
Toronto, Ontario M5G 2M9
1 trial
- NCT06628310A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Princess Margaret Cancer Centre /ID# 268715
Toronto, Ontario M5G 2M9
1 trial
- NCT06820463A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
Princess Margaret Cancer Centre /ID# 269390
Toronto, Ontario M5G 2M9
1 trial
- NCT05445778Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Princess Margaret Cancer Centre /ID# 274845
Toronto, Ontario M5G 2M9
1 trial
- NCT07005102A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Princess Margaret Cancer Centre /ID# 276275
Toronto, Ontario M5G 2M9
1 trial
- NCT05005403Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Princess Margaret Cancer Centre /ID# 276852
Toronto, Ontario M5G 2M9
1 trial
- NCT07241039A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
Princess Margaret Cancer Centre (Princess Margaret Hospital)
Toronto, Ontario M5G 2M9
1 trial
- NCT03031821Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome
Princess Margaret Cancer Centre (Site 0004)
Toronto, Ontario M5G 2M9
1 trial
- NCT04949256Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).
Princess Margaret Cancer Centre (Site 0005)
Toronto, Ontario M5G 2M9
1 trial
- NCT04489888A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10)
Princess Margaret Cancer Centre (Site 0011)
Toronto, Ontario M5G 2M9
1 trial
- NCT04210115Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
Princess Margaret Cancer Centre (Site 0050)
Toronto, Ontario M5G 2M9
1 trial
- NCT03713593Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)
Princess Margaret Cancer Centre (Site 0059)
Toronto, Ontario M5G 2M9
1 trial
- NCT03553836Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
Princess Margaret Cancer Centre (Site 0100)
Toronto, Ontario M5G 2M9
1 trial
- NCT03598608Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)
Princess Margaret Cancer Centre (Site 0103)
Toronto, Ontario M5G 2M9
1 trial
- NCT03036488Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)
Princess Margaret Cancer Centre (Site 0109)
Toronto, Ontario M5G 2M9
1 trial
- NCT03425643Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
Princess Margaret Cancer Centre (Site 0123)
Toronto, Ontario M5G 2M9
1 trial
- NCT07419295A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
  Contact: Study Coordinator
Princess Margaret Cancer Centre (Site 0153)
Toronto, Ontario M5G 2M9
1 trial
- NCT03711032Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
Princess Margaret Cancer Centre (Site 0200)
Toronto, Ontario M5G 1Z5
1 trial
- NCT04199104A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)
Princess Margaret Cancer Centre (Site 0204)
Toronto, Ontario M5G 2M9
1 trial
- NCT06074588Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
Princess Margaret Cancer Centre (Site 0208)
Toronto, Ontario M5G 2M9
1 trial
- NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
  Contact: Study Coordinator
Princess Margaret Cancer Centre (Site 0209)
Toronto, Ontario M5G 1X6
1 trial
- NCT04456699Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)
Princess Margaret Cancer Centre (Site 0301)
Toronto, Ontario M5G 2M9
1 trial
- NCT07519772A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
  Contact: Study Coordinator
Princess Margaret Cancer Centre (Site 0309)
Toronto, Ontario M5G 2M9
1 trial
- NCT03516981A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)
Princess Margaret Cancer Centre (Site 0330)
Toronto, Ontario M5G 2M9
1 trial
- NCT06136624Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
  Contact: Study Coordinator
Princess Margaret Cancer Centre (Site 0400)
Toronto, Ontario M5G 2M9
1 trial
- NCT06393374Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
  Contact: Study Coordinator
Princess Margaret Cancer Centre (Site 0409)
Toronto, Ontario M5G 2M9
1 trial
- NCT03884101Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)
Princess Margaret Cancer Centre (Site 0510)
Toronto, Ontario M5G 2M9
1 trial
- NCT05173987Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
Princess Margaret Cancer Centre (Site 0518)
Toronto, Ontario M5G 2M9
1 trial
- NCT06824467A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
  Contact: Study Coordinator
Princess Margaret Cancer Centre (Site 0601)
Toronto, Ontario M5G 2M9
1 trial
- NCT07216703A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
  Contact: Study Coordinator
Princess Margaret Cancer Centre (Site 0606)
Toronto, Ontario M5G 2M9
1 trial
- NCT06036836Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
Princess Margaret Cancer Centre (Site 1056)
Toronto, Ontario M5G 2M9
1 trial
- NCT05007106MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
Princess Margaret Cancer Centre (Site 1101)
Toronto, Ontario M5G 1Z5
1 trial
- NCT04626479Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
Princess Margaret Cancer Centre (Site 1104)
Toronto, Ontario M5G 2M9
1 trial
- NCT03179436Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)
Princess Margaret Cancer Centre (Site 1106)
Toronto, Ontario M5G 2M9
1 trial
- NCT05562830A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
Princess Margaret Cancer Centre (Site 1502)
Toronto, Ontario M5G 2M9
1 trial
- NCT03976375Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)
Princess Margaret Cancer Centre (Site 1504)
Toronto, Ontario M5G 2M9
1 trial
- NCT04704219Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)
Princess Margaret Cancer Centre (Site 1732)
Toronto, Ontario M5G 2M9
1 trial
- NCT03635567Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)
Princess Margaret Cancer Centre (Site 2001)
Toronto, Ontario M5G 2M9
1 trial
- NCT06460961A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)
Princess Margaret Cancer Centre (Site 3003)
Toronto, Ontario M5G 2M9
1 trial
- NCT04938817Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
Princess Margaret Cancer Centre (Site 3101)
Toronto, Ontario M5G 1Z5
1 trial
- NCT04626518Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
Princess Margaret Cancer Centre (Site 3106)
Toronto, Ontario M5G 2M9
1 trial
- NCT05845814A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
Princess Margaret Cancer Centre (Site 3703)
Toronto, Ontario M5G 2M9
1 trial
- NCT05239728A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
Princess Margaret Cancer Centre (Site 4002)
Toronto, Ontario M5G 2M9
1 trial
- NCT07722611A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025).
  Contact: Study Coordinator
Princess Margaret Cancer Centre (Site 4106)
Toronto, Ontario M5G 2M9
1 trial
- NCT06483334A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
Princess Margaret Cancer Centre - UHN
Toronto, Ontario M5G 2C4
1 trial
- NCT06777316A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
Princess Margaret Hospital (Hong Kong)
Toronto, M5G 2M9
1 trial
- NCT05307705A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
Princess Margaret Hospital/Ontario Cancer Institute (Data Analysis Only)
Toronto, Ontario
1 trial
- NCT03808662Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung
Princess Margaret Hospital.. (Site 0202)
Toronto, Ontario M5G 2M9
1 trial
- NCT03740165Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)
Princess Margaret Hospital - Toronto
Toronto, Ontario M5G 2M9
1 trial
- NCT02467270Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses
The Princess Margaret Cancer Center
Toronto, Ontario M5G 2C$
1 trial
- NCT06983743A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
  Contact: Erasca Clinical Team Team
UHN Blood and Marrow Transplant (BMT) Program (Princess Margaret) Cancer Center
Toronto
1 trial
- NCT05305040Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
UHN - Princess Margaret Cancer Center (Ontario)
Toronto, Ontario M5G 2M9
1 trial
- NCT05712694Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
Uninversity Health Network - Princess Margaret Cancer Center
Toronto, Ontario M5G 2M9
1 trial
- NCT03391466Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

Conditions

Diseases this institution publishes on or runs trials for.

Lung cancer175 works · 107 trials
Liver and biliary tract cancer105 works · 29 trials
Prostate cancer101 works · 45 trials
Ovarian cancer64 works · 52 trials
Sarcoma63 works · 25 trials
Melanoma62 works · 55 trials
Acute myeloid leukaemia60 works · 19 trials
Head and neck cancer41 works · 48 trials
Pancreatic cancer38 works · 47 trials
Multiple myeloma38 works · 31 trials
Bladder cancer36 works · 30 trials
Hodgkin lymphoma29 works · 3 trials
Triple-negative breast cancer28 works · 19 trials
Kidney cancer26 works · 17 trials
Metastatic breast cancer26 works · 18 trials
Glioblastoma25 works · 7 trials
Chronic myeloid leukaemia23 works · 9 trials
Endometrial cancer22 works · 20 trials
Myeloproliferative neoplasms22 works · 23 trials
Diffuse large B-cell lymphoma18 works · 13 trials
Follicular lymphoma13 works · 6 trials
Acute lymphoblastic leukaemia13 works · 5 trials
Myelodysplastic syndromes11 works · 16 trials
Mesothelioma10 works · 4 trials
Thyroid cancer10 works · 5 trials
Childhood cancers10 works · 41 trials
Meningioma8 works · 1 trial

Institution data: ROR 03zayce58 (CC0-1.0)Updated 12 Nov 2026

Report an error